

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number
WO 03/016471 A2

(51) International Patent Classification⁷: **C12N**

(21) International Application Number: PCT/US02/25603

(22) International Filing Date: 13 August 2002 (13.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/312,123 13 August 2001 (13.08.2001) US

(71) Applicant (for all designated States except US):
DANA-FARBER CANCER INSTITUTE, INC.
[US/US]; 44 Binney Street, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Lan, Bo**
[—/US]; 184 East Emmerson Road, Lexington, MA 02420
(US). **DAI, Meiru** [CN/US]; Apt. 3, 81 Washington Street,
Malden, MA 02148 (US). **SASAKI, Hidefumi** [JP/JP];
3-53-12 Heiwagaoka, Meito-ku, Nagoya 465-0097 (JP).
AUCLAIR, Daniel [CA/US]; 2 Alonquin Trail, Ashland,
MA 01721 (US).

(74) Agent: **FRASER, Janis, K.**; Fish & Richardson P.C., 225
Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent
(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PERIOSTIN-BASED DIAGNOSTIC ASSAYS

(57) Abstract: The invention includes novel human periostin polypeptides and DNAs encoding them. Also embraced by the inven-
tion are human periostin specific antibodies, diagnostic assays for metastasis of breast cancer to bone, and preeclampsia.



WO 03/016471 A2

PERIOSTIN-BASED DIAGNOSTIC ASSAYS

This application claims priority of U.S. provisional application no. 60/312,123, filed August 13, 2001.

TECHNICAL FIELD

This invention relates to methods of diagnosis, and more particularly to methods of diagnosing metastasis of breast cancer to bone and preeclampsia.

BACKGROUND

Metastatic bone tumors are the most common type of malignant bone lesion seen in adults, and are the most frequent metastatic site after lung and liver [Yoneda et al. (2000) J. Orthop. Sci. 5(1):75-81]. Both osteoblastic and osteolytic bone metastases are major causes of increased morbidity and eventual mortality in breast cancer patients. Approximately 75% of women who die of breast cancer display bone metastases at autopsy [Galasko, Incidence and distribution of skeletal metastases. *In*: C.S.B. Galasko (ed.) Skeletal Metastases. pp. 14-21, Butterworth, London, 1986; Rubens, The nature of metastatic bone disease. *In*: Bone Metastases. Diagnosis and Treatment, pp. 1-10, Springer, London, 1991].

Preeclampsia is among the most frequent causes of maternal death and perinatal mortality [Roberts et al. (1993) Lancet 341:1447-1451].

In light of the above considerations, it is important that there be available simple and reliable tests for metastasis of breast cancer to bone and preeclampsia.

SUMMARY

The inventors have identified novel human deletion variants of the protein originally designated osteoblast-specific factor-2 (OSF-2) and now called periostin [Takeshita et al. (1993) Biochem. J. 294:272-278; Horiuchi et al. (1999) J. Bone Miner. Res. 14:1239-1249]. One of the novel periostin variants was isolated from colon cancer cells and is designated TCG1. Text that refers to periostin without specifying a particular variant is pertinent to all the variants disclosed herein. The invention includes these novel periostin polypeptides, DNAs encoding them, vectors containing the DNAs, and cells containing the vectors. The invention also features antibodies,

including monoclonal antibodies (mAbs), specific for human periostin and assays using such antibodies for measuring periostin in samples (e.g., blood samples). In addition, the invention embodies methods for diagnosing metastasis of breast cancer to bone and preeclampsia.

More specifically, the invention features a purified antibody that binds specifically to human periostin. The antibody can be a polyclonal antibody or a monoclonal antibody (mAb), e.g., a mAb secreted by the 5H8 hybridoma (ATCC accession no. CRL-2646), the 8H11 hybridoma (ATCC accession no. _____), the 1B11 hybridoma, the 2C6 hybridoma, the 6B1 hybridoma, the 8E3 hybridoma, the 10A3 hybridoma, or the 7E4 hybridoma. Also embodied by the invention is a hybridoma that secretes a mAb that binds to human periostin, e.g., any of the hybridomas listed above.

Another aspect of the invention is a method of detecting human periostin in a sample. The method involves: (a) contacting the sample with an antibody that binds to human periostin; and (b) determining whether the antibody binds to a component of the sample. Binding of the antibody to a component of the sample indicates the presence of periostin in the sample. The method can further include, prior to contacting the sample with the first antibody that binds to human periostin, contacting the sample with a second antibody that binds to human periostin. An epitope on human periostin to which the first antibody binds is not the same as an epitope to which the second antibody binds. The second antibody can be bound to a solid substrate. The first antibody can be a polyclonal antibody or a mAb. The mAb can be a mAb that is secreted by any of the above-mentioned hybridomas. In addition, the second antibody can be a mAb (such as any of the above-mentioned mAbs) or a polyclonal antibody. The method can comprise, for example, an immunoblot assay or an ELISA assay and the detecting step can involve detecting, for example, chemiluminescence, radioactivity or fluorescence. Alternatively, the detecting step can involve measuring, for example, absorbance of visible or ultraviolet light. The first antibody can be biotinylated and the detecting step involve the use of avidin. Alternatively, the detecting step can involve the use of an antibody that binds to an immunoglobulin molecule.

Also embraced by the invention is a method of diagnosing a metastasis of breast cancer to bone. The method involves: (a) identifying a breast cancer patient suspected of having or being at risk of having a metastasis of breast cancer to bone; and (b) measuring the level of periostin in a sample of a body fluid from the patient. An elevated level of periostin in the sample, compared to a control level of periostin, is an indication that the patient has a metastasis

of breast cancer to the bone. The body fluid can be blood or any other body fluid recited herein, e.g., urine.

Another aspect of the invention is a method of diagnosing preeclampsia in a patient. The method involves: (a) identifying a pregnant patient suspected of having or being at risk of having preeclampsia; and (b) measuring the level of periostin in a sample of a body fluid from the patient. An elevated level of periostin in the sample, compared to a control level of periostin, is an indication that the patient has preeclampsia. The body fluid can be blood or any other body fluid recited herein, e.g., urine.

Another aspect of the invention is an isolated DNA that includes a nucleic acid sequence encoding a polypeptide that contains SEQ ID NO:6 or SEQ ID NO:14; the nucleic acid sequence can be SEQ ID NO:5 or SEQ ID NO:13. Alternatively, the isolated DNA can include a nucleic acid sequence encoding a polypeptide containing SEQ ID NO:4 or SEQ ID NO:12; the nucleic acid sequence can be SEQ ID NO:3 or SEQ ID NO:11. The invention also includes a vector containing any of the above DNAs, e.g., a vector in which the nucleic acid sequence is operably linked to a transcriptional regulatory element (TRE). Also included in the invention is a cell containing any of the above vectors.

Also featured by invention is an isolated polypeptide containing SEQ ID NO:4 or SEQ ID NO:6, SEQ ID NO:12 or SEQ ID NO:14. The invention also provides an antigenic fragment of any of the polypeptides. The fragment is shorter than the full-length polypeptide. The fragment can contain, consecutively, residues 725 and 726 of SEQ ID NO:4 or residues 768-771 of SEQ ID NO:12. Also embraced by the invention is a method of making any of the polypeptides of the invention. The method involves: (a) culturing any of the cells of the invention, provided that the vector that the cell contains includes a TRE operably linked to nucleic acid sequence encoding the polypeptide; and (b) isolating the polypeptide from the culture.

"Polypeptide" and "protein" are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification.

The term "isolated" polypeptide or peptide fragment as used herein refers to a polypeptide or a peptide fragment which either has no naturally-occurring counterpart or has been separated or purified from components which naturally accompany it, e.g., in normal tissues such as lung, kidney, or placenta, tumor tissue such as colon cancer tissue, or body fluids

such as blood, serum, or urine. Typically, the polypeptide or peptide fragment is considered "isolated" when it is at least 70%, by dry weight, free from the proteins and other naturally-occurring organic molecules with which it is naturally associated. Preferably, a preparation of a polypeptide (or peptide fragment thereof) of the invention is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, the polypeptide (or the peptide fragment thereof), respectively, of the invention. Thus, for example, a preparation of polypeptide x is at least 80%, more preferably at least 90%, and most preferably at least 99%, by dry weight, polypeptide x. Since a polypeptide that is chemically synthesized is, by its nature, separated from the components that naturally accompany it, the synthetic polypeptide is "isolated."

An isolated polypeptide (or peptide fragment) of the invention can be obtained, for example, by extraction from a natural source (e.g., from tissues or bodily fluids); by expression of a recombinant nucleic acid encoding the polypeptide; or by chemical synthesis. A polypeptide that is produced in a cellular system different from the source from which it naturally originates is "isolated," because it will necessarily be free of components which naturally accompany it. The degree of isolation or purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

An "isolated DNA" is either (1) a DNA that contains sequence not identical to that of any naturally occurring sequence, or (2) in the context of a DNA with a naturally-occurring sequence (e.g., a cDNA or genomic DNA), a DNA free of at least one of the genes that flank the gene containing the DNA of interest in the genome of the organism in which the gene containing the DNA of interest naturally occurs. The term therefore includes a recombinant DNA incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote. The term also includes a separate molecule such as: a cDNA where the corresponding genomic DNA has introns and therefore a different sequence; a genomic fragment that lacks at least one of the flanking genes; a fragment of cDNA or genomic DNA produced by polymerase chain reaction (PCR) and that lacks at least one of the flanking genes; a restriction fragment that lacks at least one of the flanking genes; a DNA encoding a non-naturally occurring protein such as a fusion protein, mutein, or fragment of a given protein; and a nucleic acid which is a degenerate variant of a cDNA or a naturally occurring nucleic acid. Also included is a recombinant DNA that includes a portion of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:11, or

SEQ ID NO:13. The term "isolated DNA" does not include a DNA present within, for example, cDNA or genomic DNA libraries or genomic DNA restriction digests in, for example, a restriction digest reaction mixture or an electrophoretic gel slice.

As used herein, an "antigenic fragment" of a periostin polypeptide is a fragment of the polypeptide that is shorter than the full-length polypeptide and has at least 5% (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, 100%, or more) of the ability of the full-length polypeptide to bind to an antibody specific for periostin. Fragments of interest can be made by recombinant, synthetic, or proteolytic digestive methods. Such fragments can then be isolated and tested for their ability to bind to an antibody specific for periostin by methods known in the art. As used herein, "full-length" periostin is immature periostin and thus includes the periostin native signal sequence.

As used herein, an expression control sequence that is "operably linked" to a coding sequence is incorporated into a genetic construct so that the expression control sequence effectively controls expression of the coding sequence.

As used herein, the term "antibody" refers not only to whole antibody molecules, but also to antigen-binding fragments, e.g., Fab, F(ab')₂, Fv, and single chain Fv (scFv) fragments. As used herein, a "scFv" fragment is a recombinant fragment of an antibody molecule that contains, in a single polypeptide chain, the antigen-binding regions of an immunoglobulin (Ig) heavy and an Ig light chain. scFv fragments generally either contain (a) no Ig heavy or Ig light chain constant regions or (b) less than the whole constant region of an Ig heavy and/or Ig light chain. Also included are chimeric antibodies.

As used herein, "testing for expression of a periostin gene in non-small cell cancer (NSCLC) tissue" means testing for expression of a periostin gene in NSCLC cells and stromal cells within and immediately surrounding the tumor as it occurs *in vivo*.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein

are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

Other features and advantages of the invention, e.g., testing for metastasis of breast cancer to bone, will be apparent from the following description, from the drawings and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1A is a depiction of the nucleotide sequence (SEQ ID NO:1) of cDNA encoding full-length OSF-2.

FIG. 1B is a depiction of the amino acid sequence (SEQ ID NO:2) of full-length OSF-2.

FIG. 2A is a depiction of the nucleotide sequence (SEQ ID NO:3) of cDNA encoding full-length periostin-L.

FIG. 2B is a depiction of the amino acid sequence (SEQ ID NO:4) of full-length periostin-L.

FIG. 3A is a depiction of the nucleotide sequence (SEQ ID NO:7) of cDNA encoding full-length periostin-K.

FIG. 3B is a depiction of the amino acid sequence (SEQ ID NO:8) of full-length periostin-K.

FIG. 4A is a depiction of the nucleotide sequence (SEQ ID NO:11) of cDNA encoding full-length periostin-C (TCG1).

FIG. 4B is a depiction of amino acid sequence (SEQ ID NO:12) of full-length periostin-C (TCG1).

FIG. 5 is a schematic representation of the periostin-C (TCG1) molecule showing the relative positions of an N-terminal leader sequence, a cysteine-rich domain ("CRD"), four internal homologous repeats ("1", "2", "3", and "4"), and a C-terminal domain that varies between periostin variants ("Variable C-terminus").

DETAILED DESCRIPTION

Sequencing of cDNA products of a reverse transcription-polymerase chain reaction (RT-PCR) analysis of RNA isolated from various tissues revealed novel splice variants of human periostin. One variant that is expressed in placenta and lung is referred to herein as periostin-L.

Another that is expressed in kidney is designated periostin-K. In addition, screening of a human carcinoma cDNA library with a DNA fragment derived by differential display of cDNA derived from colon cancer tissue and from normal colon tissue identified a transcript that is over-expressed in colon cancer cells. The cDNA molecule identified encodes another variant (designated herein as TCG1 or periostin-C) of the periostin molecule.

The inventors have also produced a polyclonal antibody (E17) and a variety of monoclonal antibodies that bind to periostin. Using these antibodies, they have also developed a "sandwich" ELISA assay using chemiluminescence for detection.

In clinical studies, the inventors have shown that serum levels of periostin are elevated in breast cancer patients having metastases to bone (compared to breast cancer patients having no sign of bone metastasis), and in patients with preeclampsia (compared to normotensive pregnant women). In a study of patients with a variety of lung cancers, 24% of the patients were found to have elevated serum periostin levels. Moreover, all the patients with very high levels (i.e., > 1,000 ng/ml) have died. These findings suggest that periostin is a marker for cancer (e.g., lung cancer), particularly advanced cancer. They also provide the bases for assays to diagnose bone metastasis in breast cancer and preeclampsia.

In addition, ovarian cancer cells and brain tumor cells overexpress periostin [Ismail et al. (2000) Cancer Res. 60:6744-6749; Lal et al. (1999) Cancer Res. 59:5403-5407].

Periostin Nucleic Acid Molecules

The periostin nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (*i.e.*, either a sense or an antisense strand). Segments of these molecules are also considered within the scope of the invention, and can be produced by, for example, the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule can be produced by *in vitro* transcription. Preferably, the nucleic acid molecules encode polypeptides that, regardless of length, are soluble under normal physiological conditions.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the polypeptides with SEQ ID NOS:4, 6, 12

and 14). In addition, these nucleic acid molecules are not limited to coding sequences, e.g., they can include some or all of the non-coding sequences that lie upstream or downstream from a coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell, such as the cell of a mammal. The nucleic acids can be those of a human, non-human primate (e.g., monkey), mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, dog, or cat. Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

In addition, the isolated nucleic acid molecules of the invention encompass segments that are not found as such in the natural state. Thus, the invention encompasses recombinant nucleic acid molecules (for example, isolated nucleic acid molecules encoding periostin incorporated into a vector (for example, a plasmid or viral vector) or into the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location)). Recombinant nucleic acid molecules and uses therefor are discussed further below.

Techniques associated with detection or regulation of genes are well known to skilled artisans. Such techniques can be used to diagnose and/or treat disorders associated with aberrant periostin expression.

A periostin family gene or protein can be identified based on its similarity to the relevant periostin gene or protein, respectively. For example, the identification can be based on sequence identity. The invention features isolated nucleic acid molecules which are at least 50% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to: (a) the nucleotide sequence of SEQ ID NOS: 2, 4, 6 or 8; and (b) a nucleic acid molecule which includes a segment of at least 30 (e.g., at least 50, 100, 150, 200, 250, 300, 350, 400, 500, 700, 900, 1,100, 1,400, 1,700, 2,000, 2,200, 2,250, 2,300 or 2,310) nucleotides of SEQ ID NO: 3, 5, 11 or 13.

The determination of percent identity between two sequences is accomplished using the mathematical algorithm of Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the BLASTN and BLASTP programs of Altschul et al. (1990) J. Mol. Biol. 215, 403-410. BLAST nucleotide searches are performed with the BLASTN program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to periostin encoding nucleic acids. BLAST protein searches are performed with the BLASTP program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to the

periostin polypeptide. To obtain gapped alignments for comparative purposes, Gapped BLAST is utilized as described in Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used (*See* <http://www.ncbi.nlm.nih.gov>).

Hybridization can also be used as a measure of homology between two nucleic acid sequences. A periostin-encoding nucleic acid sequence, or a portion thereof, can be used as a hybridization probe according to standard hybridization techniques. The hybridization of a periostin probe to DNA or RNA from a test source (e.g., a mammalian cell) is an indication of the presence of periostin DNA or RNA in the test source. Hybridization conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y., 6.3.1-6.3.6, 1991. Moderate hybridization conditions are defined as equivalent to hybridization in 2X sodium chloride/sodium citrate (SSC) at 30°C, followed by a wash in 1 X SSC, 0.1% SDS at 50°C. Highly stringent conditions are defined as equivalent to hybridization in 6X sodium chloride/sodium citrate (SSC) at 45°C, followed by a wash in 0.2 X SSC, 0.1% SDS at 65°C.

The invention also encompasses: (a) vectors (see below) that contain any of the foregoing periostin related coding sequences and/or their complements (that is, "antisense" sequences); (b) expression vectors that contain any of the foregoing periostin related coding sequences operably linked to any transcriptional/translational regulatory elements (examples of which are given below) necessary to direct expression of the coding sequences; (c) expression vectors encoding, in addition to a periostin polypeptide, a sequence unrelated to periostin, such as a reporter, a marker, or a signal peptide fused to periostin; and (d) genetically engineered host cells (see below) that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention.

Recombinant nucleic acid molecules can contain a sequence encoding periostin or periostin having an heterologous signal sequence. The full length periostin polypeptide, or a fragment thereof, may be fused to such heterologous signal sequences or to additional polypeptides, as described below. Similarly, the nucleic acid molecules of the invention can encode the mature form of periostin or a form that includes an exogenous polypeptide that facilitates secretion.

The transcriptional/translational regulatory elements referred to above and further described below include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements that are known to those skilled in the art and that drive or otherwise regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, a sequence that functions as a marker or reporter. Examples of marker and reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r , G418^r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include a first portion and a second portion; the first portion being a periostin polypeptide and the second portion being, for example, the reporter described above or an Ig constant region or part of an Ig constant region, e.g., the CH2 and CH3 domains of IgG2a heavy chain. Other hybrids could include an antigenic tag or His tag to facilitate purification.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (for example, *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the nucleic acid molecule of the invention; insect cell systems infected with recombinant virus expression vectors (for example, baculovirus) containing the nucleic acid molecule of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expres-

sion vectors (for example, Ti plasmid) containing a periostin nucleotide sequence; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter). Also useful as host cells are primary or secondary cells obtained directly from a mammal and transfected with a plasmid vector or infected with a viral vector.

Cells transfected or transduced with the expression vectors of the invention can then be used, for example, for large or small scale *in vitro* production of a periostin polypeptide or antigenic fragment thereof by methods known in the art. In essence, such methods involve culturing the cells under conditions which maximize production of the polypeptide or antigenic fragment and isolating it from the cells or from the culture medium.

Periostin Polypeptides and Polypeptide Fragments

The polypeptides of the invention include periostin-L, periostin-L without a signal peptide, periostin-C, and periostin-C without a signal peptide, as well as antigenic fragments of these polypeptides. Antigenic fragments of periostin-L can include, consecutively, (a) residues 669 and 670 of SEQ ID NO: 4 and/or (b) residues 725 and 726 of SEQ ID NO:4. Antigenic fragments of periostin-C can include, consecutively, (a) residues 669 and 670 of SEQ ID NO:12 and/or (b) residues 768-771 of SEQ ID NO:12. Antigenic fragments also include the full-length forms of any of the periostin molecules but with the N-terminal 18, 19, 20, 21, 22, 23, 24, or 25 amino acid residues deleted. The polypeptides embraced by the invention also include fusion proteins that contain either full-length periostin (including any of the forms disclosed herein) or an antigenic fragment of it fused to unrelated amino acid sequence. The unrelated sequences can be additional functional domains or signal peptides. Signal peptides are described in greater detail and exemplified below. The polypeptides can be any of those described above but with not more than 50 (i.e., not more than: 50; 40; 30; 20; 15; 12; 10; nine; eight; seven; six; five; four; three; two; or one) conservative substitutions.

The amino acid sequences of the periostin molecules and antigenic fragments thereof can be identical to the wild-type sequences of the periostin molecules and the sequences of the fragments as they occur in the wild-type periostin molecules, respectively. Alternatively, any of

the components can contain mutations such as deletions, additions, or substitutions. All that is required is that the mutant periostin molecule have at least 5% (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 100%, or even more) of the ability of the wild-type periostin molecule or the antigenic fragment as it occurs in the wild-type periostin molecule to bind to an antibody specific for wild-type periostin. Substitutions will preferably be conservative substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.

The polypeptides can be purified from natural sources (e.g., blood, serum, plasma, tissues or cells such as normal lung or placenta or colon cancer tissue, or any cell that naturally produces periostin polypeptides). The periostin molecules and antigenic fragments can be those of a human, non-human primate (e.g., a monkey), mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, dog, or cat. Smaller peptides (less than 100 amino acids long) can also be conveniently synthesized by standard chemical means. In addition, both polypeptides and peptides can be produced by standard *in vitro* recombinant DNA techniques and *in vivo* transgenesis using nucleotide sequences encoding the appropriate polypeptides or peptides. Methods well-known to those skilled in the art can be used to construct expression vectors containing relevant coding sequences and appropriate transcriptional/translational control signals. See, for example, the techniques described in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2nd Ed.) [Cold Spring Harbor Laboratory, N.Y., 1989], and Ausubel et al., *Current Protocols in Molecular Biology* [Green Publishing Associates and Wiley Interscience, N.Y., 1989].

The polypeptides and antigenic fragments of the invention can be used to generate anti-periostin antibodies or for basic studies on periostin function, e.g., investigations into the significance of its association with various cancers and preeclampsia. The polypeptides and functional fragments can also be used as positive controls in the diagnostic assays of the invention (see below).

Polypeptides and fragments of the invention also include those described above, but modified for *in vivo* use by the addition, at the amino- and/or carboxyl-terminal ends, of a blocking agent to facilitate survival of the relevant polypeptide *in vivo*. This can be useful in those situations in which the peptide termini tend to be degraded by proteases prior to cellular

uptake. Such blocking agents can include, without limitation, additional related or unrelated peptide sequences that can be attached to the amino and/or carboxyl terminal residues of the peptide to be administered. This can be done either chemically during the synthesis of the peptide or by recombinant DNA technology by methods familiar to artisans of average skill.

Alternatively, blocking agents such as pyroglutamic acid or other molecules known in the art can be attached to the amino and/or carboxyl terminal residues, or the amino group at the amino terminus or carboxyl group at the carboxyl terminus can be replaced with a different moiety. Likewise, the peptides can be covalently or noncovalently coupled to pharmaceutically acceptable "carrier" proteins prior to administration.

Also of interest are peptidomimetic compounds that are designed based upon the amino acid sequences of the functional peptide fragments. Peptidomimetic compounds are synthetic compounds having a three-dimensional conformation (i.e., a "peptide motif") that is substantially the same as the three-dimensional conformation of a selected peptide. The peptide motif provides the peptidomimetic compound with the ability to bind to an antibody specific for periostin in a manner qualitatively identical to that of the periostin functional fragment from which the peptidomimetic was derived. Peptidomimetic compounds can have additional characteristics that enhance their *in vivo* utility, such as increased cell permeability and prolonged biological half-life.

The peptidomimetics typically have a backbone that is partially or completely non-peptide, but with side groups that are identical to the side groups of the amino acid residues that occur in the peptide on which the peptidomimetic is based. Several types of chemical bonds, e.g., ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.

The *in vivo* half life of the polypeptides or polypeptide fragments of the invention can also be prolonged by substitution of all or some of the L-amino acid residues of the native molecule or functional fragment with D-amino acids.

Periostin Antibodies

The invention features antibodies that bind specifically to any of the periostin polypeptides or fragments of such polypeptides. Such antibodies can be polyclonal antibodies

present in the serum or plasma of animals (e.g., mice, rabbits, rats, guinea pigs, sheep, horses, goats, cows, or pigs) that have been immunized with the relevant periostin polypeptide or peptide fragment using methods, and optionally adjuvants, known in the art. Such polyclonal antibodies can be isolated from, for example, serum, plasma, or ascites by methods known in the art. An example of such a polyclonal antibody is the E17 polyclonal antibody. Monoclonal antibodies that bind to the above polypeptides or fragments are also encompassed by the invention.

Methods of making and screening monoclonal antibodies are well known in the art.

Once the desired antibody-producing hybridoma has been selected and cloned, the resultant antibody can be produced by a number of *in vivo* and *in vitro* methods known in the art. For example, the hybridoma can be cultured *in vitro* in a suitable medium for a suitable length of time, followed by the recovery of the desired antibody from the supernatant. The length of time and medium are known or can be readily determined.

Additionally, recombinant antibodies specific for periostin, such as chimeric and humanized monoclonal antibodies comprising both human and non-human portions, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example, using methods described in Robinson et al., International Patent Publication PCT/US86/02269; Akira et al., European Patent Application 184,187; Taniguchi, European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988) Science 240:1041-43; Liu et al. (1987) J. Immunol. 139:3521-26; Sun et al. (1987) PNAS 84:214-18; Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-49; Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-59; Morrison, (1985) Science 229:1202-07; Oi et al. (1986) BioTechniques 4:214; Winter, U.S. Patent No. 5,225,539; Jones et al. (1986) Nature 321:552-25; Veroeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-60.

Also included within the scope of the invention are antibody fragments and derivatives which contain at least the functional portion of the antigen binding domain of an antibody that binds specifically to periostin. Antibody fragments that contain the binding domain of the molecule can be generated by known techniques. For example, such fragments include, but are not limited to: F(ab')₂ fragments that can be produced by pepsin digestion of antibody molecules;

Fab fragments that can be generated by reducing the disulfide bridges of F(ab')₂ fragments; and Fab fragments that can be generated by treating antibody molecules with papain and a reducing agent. See, e.g., National Institutes of Health, 1 Current Protocols In Immunology, Coligan *et al.*, ed. 2.8, 2.10 (Wiley Interscience, 1991). Antibody fragments also include Fv (e.g., single chain Fv (scFv)) fragments, *i.e.*, antibody products in which there are few or no constant region amino acid residues. An scFv fragment is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the ScFv is derived. Such fragments can be produced, for example, as described in U.S. Patent No. 4,642,334, which is incorporated herein by reference in its entirety.

The antibodies of the invention can bind to all periostin splice variants, a subgroup of splice variants, or a single splice variant. Ways for making and screening for splice variant-specific antibodies are known to those in the art. For example, if it were desired to make an antibody specific for a periostin domain absent in periostin variant x but present in periostin variant y, one could immunize an animal (e.g., a mouse) with periostin variant y and select for antibodies that bind to periostin variant y but not to periostin variant x. Alternatively, the animal could be immunized with a functional fragment of periostin composed of the domain of interest. Antibodies could be selected on the basis of their ability to bind to the functional fragment of periostin and variant y and their inability to bind to variant x.

Applicants have deposited under the Budapest Treaty the 5H8 and 8H11 hybridomas with the American Type Culture Collection (ATCC), Rockville, MD 20852, U.S.A. The 5H8 hybridoma was assigned the ATCC accession no. CRL-2646 and the 8H11 hybridoma the ATCC accession no. _____. The hybridomas deposited with the ATCC were taken from a deposit maintained by the Dana Farber Cancer Institute, Inc., since prior to the priority date of this application. The deposits of hybridomas will be maintained without restriction in the ATCC depository for a period of 30 years, or five years after the most recent request, or for the effective life of the patent, whichever is the longer, and will be replaced if the deposit becomes non-viable during that period.

Diagnostic assays

The invention features diagnostic assays. Such assays are based on the findings that serum levels of periostin are elevated in breast cancer patients having metastases to bone

(compared to breast cancer patients having no sign of bone metastasis) and in patients with preeclampsia (compared to normotensive pregnant women). These findings provide the bases for assays to diagnose bone metastasis in breast cancer and preeclampsia. Such assays can be used on their own or, preferably, in conjunction with other procedures to test for the relevant clinical condition.

In the assays of the invention either: (1) the presence of periostin protein or periostin mRNA in cancer tissue (including surrounding stromal cells) is tested for or their levels are measured; or (2) the level of periostin protein is measured in a liquid sample such as a body fluid (e.g., urine, saliva, semen, blood, or serum or plasma derived from blood); a lavage such as a lung lavage, a gastric lavage, a rectal or colonic lavage, or a vaginal lavage; or a fluid such as a supernatant from a cell culture. In order to test for the presence or measure the level of periostin mRNA in cells, the cells can be lysed and total RNA can be purified or semi-purified from the lysates by any of a variety of methods known to those in the art. Methods of detecting or measuring levels of particular mRNA transcripts are also familiar to those in the art. Such assays include, without limitation, hybridization assays using detectably labeled periostin-specific DNA or probes and quantitative or semi-quantitative RT-PCR methodologies employing appropriate periostin-specific oligonucleotide primers (see Example 1). Additional methods for quantitating mRNA in cell lysates include RNA protection assays and serial analysis of gene expression (SAGE). Alternatively, qualitative, quantitative, or semi-quantitative *in situ* hybridization assays can be carried out using, for example, tissue sections or unlysed cell suspensions, and detectably (e.g., fluorescently or enzyme) labeled DNA or RNA probes.

Methods of detecting or measuring the levels of a protein of interest (e.g., periostin) in cells are known in the art. Many such methods employ antibodies (e.g., polyclonal antibodies or mAbs) that bind specifically to the protein. In such assays, the antibody itself or a secondary antibody that binds to it can be detectably labeled. Alternatively, the antibody can be conjugated with biotin, and detectably labeled avidin (a protein that binds to biotin) can be used to detect the presence of the biotinylated antibody. Combinations of these approaches (including "multi-layer" assays) familiar to those in the art can be used to enhance the sensitivity of assays. Some of these assays (e.g., immunohistological methods or fluorescence flow cytometry) can be applied to histological sections or unlysed cell suspensions. The methods described below for detecting periostin in a liquid sample can also be used to detect periostin in cell lysates.

Methods of detecting periostin in a liquid sample (see above) basically involve contacting a sample suspected of containing periostin with an antibody of the invention and testing for binding of the antibody to a component of the sample. In such assays the antibody need not be detectably labeled and can be used without a second antibody that binds to periostin. For example, by exploiting the phenomenon of surface plasmon resonance, an antibody specific for periostin bound to an appropriate solid substrate is exposed to the sample. Binding of periostin to the antibody on the solid substrate results in a change in the intensity of surface plasmon resonance that can be detected qualitatively or quantitatively by an appropriate instrument, e.g., a Biacore apparatus (Biacore International AB, Rapskatan, Sweden).

Moreover, assays for detection of periostin in a liquid sample can involve the use, for example, of: (a) a single periostin-specific antibody that is detectably labeled; (b) an unlabeled periostin-specific antibody and a detectably labeled secondary antibody; or (c) a biotinylated periostin-specific antibody and detectably labeled avidin. In addition, as described above for detection of proteins in cells, combinations of these approaches (including "multi-layer" assays) familiar to those in the art can be used to enhance the sensitivity of assays. In these assays, the sample or an (aliquot of the sample) suspected of containing periostin can be immobilized on a solid substrate such as a nylon or nitrocellulose membrane by, for example, "spotting" an aliquot of the liquid sample or by blotting of an electrophoretic gel on which the sample or an aliquot of the sample has been subjected to electrophoretic separation. The presence or amount of periostin on the solid substrate is then assayed using any of the above described forms of the periostin-specific antibody and, where required, appropriate detectably labeled secondary antibodies or avidin.

The invention also features "sandwich" assays. In these sandwich assays, instead of immobilizing samples on solid substrates by the methods described above, any periostin that may be present in a sample can be immobilized on the solid substrate by, prior to exposing the solid substrate to the sample, conjugating a second ("capture") periostin-specific antibody (polyclonal or mAb) to the solid substrate by any of a variety of methods known in the art (e.g., see Example 1 below). In exposing the sample to the solid substrate with the second periostin-specific antibody bound to it, any periostin in the sample (or sample aliquot) will bind to the second periostin-specific antibody on the solid substrate. The presence or amount of periostin bound to the conjugated second periostin-specific antibody is then assayed using a "detection" periostin-

specific antibody by methods essentially the same as those described above using a single periostin-specific antibody. It is understood that in these sandwich assays, the capture antibody should not bind to the same epitope (or range of epitopes in the case of a polyclonal antibody) as the detection antibody. Thus, if a mAb is used as a capture antibody, the detection antibody can be either: (a) another mAb that binds to an epitope that is either completely physically separated from or only partially overlaps with the epitope to which the capture mAb binds; or (b) a polyclonal antibody that binds to epitopes other than or in addition to that to which the capture mAb binds. On the other hand, if a polyclonal antibody is used as a capture antibody, the detection antibody can be either: (a) a mAb that binds to an epitope to that is either completely physically separated from or partially overlaps with any of the epitopes to which the capture polyclonal antibody binds; or (b) a polyclonal antibody that binds to epitopes other than or in addition to that to which the capture polyclonal antibody binds. Assays which involve the use of a capture and detection antibody include sandwich ELISA assays, sandwich Western blotting assays, and sandwich immunomagnetic detection assays.

Suitable solid substrates to which the capture antibody can be bound include, without limitation, the plastic bottoms and sides of wells of microtiter plates, membranes such as nylon or nitrocellulose membranes, polymeric (e.g., without limitation, agarose, cellulose, or polyacrylamide) beads or particles. It is noted that periostin-specific antibodies bound to such beads or particles can also be used for immunoaffinity purification of periostin.

Methods of detecting or for quantifying a detectable label depend on the nature of the label and are known in the art. Appropriate labels include, without limitation, radionuclides (e.g., ^{125}I , ^{131}I , ^{35}S , ^3H , ^{32}P , or ^{14}C), fluorescent moieties (e.g., fluorescein, rhodamine, or phycoerythrin), luminescent moieties (e.g., Qdot™ nanoparticles supplied by the Quantum Dot Corporation, Palo Alto, CA), compounds that absorb light of a defined wavelength, or enzymes (e.g., alkaline phosphatase or horseradish peroxidase). The products of reactions catalyzed by appropriate enzymes can be, without limitation, fluorescent, luminescent, or radioactive or they may absorb visible or ultraviolet light. Examples of detectors include, without limitation, x-ray film, radioactivity counters, scintillation counters, spectrophotometers, colorimeters, fluorometers, luminometers, and densitometers.

In assays to diagnose metastasis of breast cancer to bone, the concentration of periostin in, for example, serum from a breast cancer patient suspected of having one or more metastases

to bone is compared to a control value. This control value can be, for example, the mean of the concentrations of periostin in a control group of breast cancer patients in whom no bone metastases have been detected. Alternatively, the levels of periostin in the serum of the patient can be measured at various times after a diagnosis of breast cancer. An increase in the level of periostin detected in the serum at a particular time point relative to prior measurements would indicate that the patient's breast cancer had metastasized to bone. In this case the relevant prior measurement would be the control value. A significantly higher concentration of periostin in the serum of the patient relative to the control value would indicate that the patient has a metastasis to bone of her breast cancer.

In assays to diagnose preeclampsia, the patient's serum level of periostin is compared to a control value. The control value can be, for example, the mean of the concentrations of periostin in the sera of control group of normotensive pregnant women. The serum sample from the patient and the control subjects should be obtained at approximately the same stage of pregnancy. Significantly increased levels of periostin in the sera of preeclampsia patients can be detected as early as the first trimester with levels rising with time of gestation. Thus another control value could be the serum level of periostin in a patient of interest at an earlier stage of her pregnancy. A significantly higher concentration of periostin in the serum of the patient relative to the control value would indicate that the patient had preeclampsia.

It is understood that, while the above descriptions of the diagnostic assays refer to assays on serum, the assays can also be carried out on any of the other fluid samples listed herein. In addition, it is noted that the patients and control subjects referred to above need not be human patients. They can be for example, non-human primates (e.g., monkeys), horses, sheep, cattle, goats, pigs, dogs, guinea pigs, hamsters, rats, rabbits or mice.

The following examples are meant to illustrate, not limit, the invention.

EXAMPLES

Example 1. Methods and Materials

Patients in study on bone metastasis

The study groups included 58 breast cancer and 44 small cell lung cancer patients who had undergone neoadjuvant chemotherapy and/or bone marrow transplantation at the Dana-Farber Cancer Institute.

Blood samples for all studies were collected and processed within 2 hours of collection. Sera were stored at -80 °C until assay.

Patients in study on preeclampsia

Thirty nulliparous pregnant women with preeclampsia were matched according to gestational stage with 30 nulliparous normal pregnant women at Magee-Womens Hospital (Pittsburgh, PA). Blood samples were obtained in the third trimester (at approximately week 36 of pregnancy) with informed consent as part of an institutional review board-approved longitudinal study of preeclampsia at Magee-Womens Research Institute (University of Pittsburgh, Pittsburgh, PA). Preeclampsia was diagnosed in women in their first full term pregnancy whose blood pressure increased by 15 mm Hg diastolic or 30 mm Hg systolic and had proteinuria (300 mg /24 hours or 1+ on a catheterized urine or 2+ on a voided urine or 0.3 on a protein creatinine ratio and hyperuricemia > 1SD above normal values for their stage of gestation). None of the patients in this study had an equivocal blood pressure increase i.e., all patients had sustained systolic blood pressures of at least 140 mm Hg and sustained diastolic blood pressures of 90 mm Hg.

Production of antibodies

The expression vector CMV-6xHis-Periostin contains a cDNA sequence encoding mature human periostin-C (see below) linked to: (a) a heterologous leader sequence; and (b) via an enterokinase recognition sequence to a hexa-histidine sequence. The expression vector CMV-Fc-Periostin contains a cDNA sequence encoding mature human periostin-C linked to: (a) a heterologous leader sequence; and (b) a mouse immunoglobulin γ_{2a} heavy chain constant region ("Fc-periostin") [Lo et al. (1998) Protein Eng. 11:495-500]. Both expression vectors were transfected by electroporation of the NS/0 mouse myeloma cell line, and stably transfected cells were selected with methotrexate. Periostin produced by the CMV-6xHis-Periostin-transfected cell line ("His-periostin") was purified from culture supernatant using the HisBind Purification Kit (Novagen, Madison, WI). After cleavage of the histidine tag with enterokinase (InVitrogen, Carlsbad, CA), the periostin protein was injected into rabbits. The E17 polyclonal antibody produced by this immunization was affinity-purified on Affi-gel 10 columns (Amersham

Pharmacia Biotech, Piscataway, NJ) in which the Affi-gel 10 was conjugated to periostin produced by CMV-6xHis-Periostin-transfected cells.

Similarly, Fc-periostin was purified from culture supernatant of the CMV- Fc-Periostin-transfected cell line by Protein A affinity chromatography (Amersham Pharmacia Biotech). Fc-periostin fusion protein was injected into mice and the 5H8 monoclonal antibody (mAb) was produced using standard procedures. Seven other human periostin-specific mAb (1B11, 2C6, 6B1, 8H11, 8E3, 10A3, and 7E4) were derived by the same method. All the mAbs are of the IgG class. The 5H8 and 8H11 mAbs are of the IgG1 subclass and have kappa light chains. Purified 5H8 IgG antibody was biotinylated using the Sulfo-NHS-LS Biotinylation Kit (Pierce, Rockford, IL).

Cell culture

The mAb producing hybridomas and the malignant mesothelioma cell line, JMN1B, were cultured in DMEM (GibcoBRL, Grand Island, NY) containing 10% fetal bovine serum (GibcoBRL).

Immunohistochemistry

Sections of human invasive ductal breast cancer tissue were purchased from Novagen. The paraffin-embedded slides were deparaffinized by incubation in xylene and rehydrated in graded ethanol-water solutions. The samples were treated in a microwave oven for 15 minutes with citrate buffer (pH6.0). Endogenous peroxidases were inhibited with 0.3% H₂O₂ in methanol and non-specific protein-binding sites were blocked with normal horse serum. Staining of the sections was carried out using the Vecastain® Universal Elite® ABC kit (Vector Laboratories, Burlingame, CA). The sections were incubated overnight at 4°C with diluted affinity-purified E17 polyclonal antibody (see Example 2), and then, after washing, with the biotinylated secondary antibody for 1 hour at room temperature. After further washing, the sections were incubated for 30 minutes at room temperature with a reagent composed of a preformed macromolecular complex of avidin and biotinylated horseradish peroxidase. The substrate for the color reaction was 3,3-diaminobenzidine. Sections were counterstained with hematoxylin before mounting. A negative control slide was processed simultaneously; in this control slide “preimmune serum” was used instead of the E17 polyclonal antibody.

In situ RNA hybridization

The sections of human invasive ductal breast cancer described above and others of human squamous lung cancer tissues (also purchased from Novagen) were used for *in situ* RNA hybridization. The paraffin embedded sections were deparaffinized by incubation in xylene and rehydrated in graded ethanol water solutions. *In situ* RNA hybridization was performed as described previously [Gunn et al. (1998) Proc Natl Acad Sci USA 95(1):258-263]. A 392-bp fragment encoding the N-terminus (starting from the ATG initiation codon) of human periostin-C was excised using BamHI and EcoRI from human periostin cDNA and then cloned in pBluescript (Stratgene, La Jolla, CA). Sense and antisense probes were generated with the T3 and T7 RNA polymerases, respectively, in the presence of [³⁵S]-UTP, using the 392-bp fragment as a template. All periostin variant-encoding cDNAs characterized at this time have identical nucleotide sequences in the N-terminal region corresponding to the 392-bp fragment, and thus probes made using the fragment as a template would detect all the variant mRNA molecules.

Periostin chemiluminescence assay

Patient serum samples were diluted 2-fold with 20 mM Tris-HCl (pH 8.0) and applied to Sep-Pak™ QMA cartridges (New Bedford, MA), which were then washed with 20 mM Tris-HCl (pH 8.0) containing 0.1 M NaCl. The cartridges were then eluted with 20 mM Tris-HCl (pH 8.0) containing 0.25 M NaCl. The eluates were immediately frozen and lyophilized. Lyophilized samples were reconstituted and diluted (8-fold or 40-fold) for assay with standard diluent buffer (Tris-buffered saline (TBS), pH 7.4, containing 0.1% BSA and 0.05% Tween 20).

All samples were assayed in duplicate. Reacti-Bind™ NeutrAvidin-coated polystyrene white plates (Pierce, Rockford, IL) were pre-washed three times with diluent buffer. Biotin-conjugated 5H8 monoclonal antibody (100 µl/well) was added to each well of the avidin pre-coated plates which were then incubated overnight at 4°C. In some assays, normal plates (i.e., plates not coated with avidin) were used and in these assays 5H8 monoclonal antibody without biotin was coated directly onto the plate well bottoms. The plates were washed 3 times for 10 minutes per wash in diluent buffer. Non-specific protein-binding sites in the wells were blocked by adding PBS (phosphate buffered saline) containing bovine serum albumin (BSA; 3% w/v) to the wells and incubating the plates for 2 hours at 37°C. The plates were then washed three times

with diluent buffer. The diluted samples or purified periostin (produced using the CMV-6xHis-Periostin vector; see above) (at various concentrations as standards) were added to the wells and the plates were incubated for 3 hours at 37°C. After further washes (as above) affinity-purified polyclonal antibody E17 was added to the wells, and the plates were incubated for 2 hours at 37°C. Unbound antibody was washed away and an alkaline phosphatase-conjugated, affinity-purified antibody specific for rabbit IgG was added to all the wells (Tropix, Bedford, MA). The plates were incubated for 2 hours at 37°C. After further washes, 100 µl of Assay buffer (Tropix) was added and incubated for 10 minutes at room temperature. The Assay buffer was completely removed by inverting and tapping the plates. The CSPD (3-(4-methoxyspiro[1,2-dioxetane-3-2' (5'-chloro)-tricyclo [3.3.1.1] decan]-4yl) phenyl phosphate) chemiluminescence substrate (Tropix) was then added. Chemiluminescence intensity was read within 30 minutes using a FL 600 fluorescence microplate reader (Bio-tek Instruments, Winooski, VT) following the manufacturer's instructions.

RT-PCR assay for periostin

cDNAs synthesized from poly A+ RNA isolated from a variety of human tissues were purchased from Clontech, Palo Alto, CA. PCR was performed as follows. The oligonucleotide primer sequences designed to amplify full length periostin DNA were 5'-ATGATTCCCTTTTACCCATGTTTCTCTA-3' (forward) (SEQ ID NO:15) and 5'-TCACTGAGAACGACCTTCCCTTAATCGTCTTCTA-3'(reverse) (SEQ ID NO:16). PCR was performed for 38 cycles (30 sec. at 94°C, 45 sec. at 49°C, 150 sec. at 72°C). Six µl aliquots were subjected to electrophoresis on a 1% agarose gel, and the amplicons were visualized by ethidium bromide staining. The specificity of the PCR was confirmed by sequencing of the product. Control PCRs were performed using GAPDH specific oligonucleotide primers as described above.

Palindromic PCR cDNA display

Total cellular RNA was extracted from tumor or normal tissues (surgical specimens) or cultured cells by using Tri-reagent (Leedo Medical Lab., Houston, TX). Surgical specimens were obtained from the New England Deaconess Hospital Department of Surgery as previously

described [Barnard et al. (1992) Cancer Res., 52:3067-3072]. PolyA⁺ mRNA was purified using oligo dT magnetic beads (Promega, Madison, WI).

PolyA⁺ mRNA (100ng) from tissue was reverse transcribed to cDNA with a single palindromic primer (5'-CTGATCCATG-3') (SEQ ID NO:17) (2mM) and 0.5 unit of rTh DNA polymerase (Perkin Elmer Cetus) in the presence of MnCl₂ (1.0mM) at 70°C for 12min (total volume: 5μl) (3 cycles). Reverse transcription was followed by 40 cycles of a palindromic PCR reaction (94°C, 30 sec.; 40°C, 100 sec.; 72°C, 35 sec.) with the same palindromic primer (0.4mM) and rTh DNA polymerase in the presence of MgCl₂ (2.0mM) and [³⁵S]-dATP in the same reaction tube used for reverse transcription (total volume: 25μl). Amplified palindromic PCR products (³⁵S-labeled) were resolved on a polyacrylamide gel. cDNA patterns derived from tumor and the adjacent normal tissue were directly compared.

The cDNA bands of interest were excised and recovered from the gel. Recovered cDNA fragments were reamplified with Taq DNA polymerase (Perkin Elmer) in Tricine buffer (10mM Tricine, 50mM KCl, 1.5mM MgCl₂, 0.001% gelatin, pH 8.4) instead of standard Tris PCR buffer. Reamplified cDNA fragments were analyzed by agarose gel electrophoresis.

Statistical Methods

Statistical analyses were carried out using the Mann-Whitney U-test for unpaired samples. Linear relationships between variables were determined by means of simple linear regression. Correlation coefficients were determined by rank correlation using Spearman's test. Differences between means were tested for significance using the test of Kruskal-Wallis and Fisher's PLSD test. All analyses were done using the StatView™ software package (Abacus Concepts Inc.). Differences were considered significant when the p value was less than 0.05.

Example 2. Periostin JMN1B is a 90 kDa secreted protein

Previous studies of the inventors showed that periostin transcripts are detectable in many cancer tissues but not in any of the cancer cell lines tested except the malignant mesothelioma cell lines JMN and JMN1B [Behbehani et al. (1982) Hum Pathol, 13(9):862-866; Demetri et al. (1989) Blood, 74:940-946]. Conditioned medium of JMN1B cells was concentrated 10-fold and both this concentrate and JMN1B cell lysate were analyzed by Western blotting. The E17 polyclonal antibody preparation raised against human periostin contained antibodies that bound

to both periostin and β igH3. Western blotting with the E17 polyclonal antibody revealed both periostin and β igH3 to be more abundant in JMN1B supernatant than in cell lysate. After affinity purification with periostin bound to a solid substrate, the ability of the E17 polyclonal antibody to bind to β igH3 was eliminated leaving only the ability to bind to periostin which migrated as a 90 kDa band on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The E17 polyclonal antibody did not immunoprecipitate periostin but the 5H8 mAb did. Thus, the 5H8 monoclonal antibody was used for capture and the affinity-purified E17 polyclonal antibody for detection of periostin in "sandwich" assays for periostin.

JMN1B cells were treated with 1.5 μ M of monensin (Sigma Co., St. Louis, MO) which is an inhibitor of intracellular vesicular transport. Five hours after addition of monensin to the cell cultures, periostin could be detected by Western blotting in cell lysate but not in culture medium. In addition, the affinity-purified E17 antibody stained the Golgi of control cells. However, monensin treatment resulted in punctate cytoplasmic staining.

In toto, the above findings indicate that periostin (as expressed by JMN1B cells) is a 90 kDa secreted protein.

Example 3. Expression of periostin in breast cancer

Periostin protein could be detected by immunohistochemistry using the E17 antibody immunopurified as described above. Strong staining was seen in the invasive breast cancer cells, but the surrounding normal stromal cells were only faintly stained. Strong staining was also observed in the advancing margin of breast cancer, as opposed to the central area of the tumor. On the other hand, strong staining was not detected in sections of non-invasive, normal breast tissues. Periostin mRNA could also be detected by *in situ* RNA hybridization. High expression of the periostin gene was observed in the stromal cells surrounding breast carcinoma whereas very little expression was found in cancer cells. While the invention is not limited by any particular mechanism of action, it seems likely that the thin layer of stromal cells at the edge of the tumor secrete periostin, which then binds to the surface of the tumor cells. Naturally, it is also possible that the tumor cells are producing periostin, possibly at a lower level than the stromal cells at the edge of the tumor. No signal was seen in normal breast tissue sections.

Example 4. Serum level of periostin in cancer patients as a predictor of bone metastases

The clinical and pathological characteristics of the 58 breast cancer patients studied are shown in Table 1. These included 7 cases at stage II, 15 at stage III, and 36 at stage IV. The median age was 44.5 years (range 31-63). Among the 36 stage IV patients, 15 (42%) were diagnosed with one metastasis site, and 21 (58%) had more than two. Among a subset of 40 patients (mixed stages), the tumors in 24 (60%) were estrogen receptor-positive. In a subset of 38 patients, the tumors in 24 (63%) were progesterone receptor-positive. In a subset of 40 patients, 29 (72.5%) were premenopausal and 11 (27.5%) were postmenopausal.

TABLE 1. CLINICOPATHOLOGICAL DATA ON 58 BREAST CANCER PATIENTS

Factors	No. of patients	Serum Periostin	
		Periostin levels (ng/ml)	p-value
Mean age	44.4±1.1 years	58	0.2012 $r^2=0.0369^*$
Menopause			
Pre menopausal	29 (72.5%)	89.8±25.3	0.4309
post menopausal	11 (27.5%)	41.7±11.0	
Tumor status			
T1	11(27.5%)	65.7±15.7	NS
T2	17(42.5%)	63.6±24.7	
T3	4(10.0%)	91.8±52.8	
T4	8(20.0%)	124.4±72.8	
Stage			
II	7 (12.1%)	56.1±14.3	NS
III	15 (25.9%)	28.0±4.7	
IV	36 (62.1%)	85.3±20.5	
Bone metastasis			
negative	37 (63.8%)	55.0±16.6	0.04
positive	21 (36.2%)	89.3±21.8	
No. of metastasis sites			
one	15 (41.7%)	75.9±29.7	0.2546
more than two	21 (58.3%)	92.0±28.6	
Lymph node metastasis			
Positive	36 (78.3%)	95.3±25.0	0.5411
Negative	10 (21.7%)	44.4±8.4	
ER status			
negative	24 (60.0%)	72.1±19.0	0.8359
positive	16 (40.0%)	88.4±38.0	
PR status			
negative	24 (63.2 %)	72.3±19.1	0.9758
positive	14 (36.8%)	94.8±43.1	
Grading			
II	6(17.1%)	128.3±62.0	0.189
III	29 (82.9%)	65.8±21.1	

* Correlation of age with periostin levels for all 58 patients

NS, not significant; ER, estrogen receptor; PR, progesterone receptor

The clinical and pathological characteristics of the 44 small cell lung cancer patients are shown in Table 2. This group of patients included 32 cases at stage III and 12 cases at stage IV.

The median age was 51 years (range 26-62). Among the 12 stage IV patients, 5 had a single metastasis site, and 7 were diagnosed with more than two metastasis sites (Table 2).

TABLE 2. CLINICOPATHOLOGICAL DATA ON 44 SMALL CELL LUNG CANCER PATIENTS

Factors		No. of Patients	Serum Periostin	
			Periostin levels (ng/ml)	p-value
Mean age	51.3±7.5 years	44		0.3579 $r^2=0.0202^*$
Gender				
	Male	27 (61.4%)	79.7±12.5	0.3349
	Female	17 (38.6%)	68.2±21.3	
Tumor status				
	T1	6(14.0%)	36.3±7.5	T4 vs T2
	T2	14(31.8%)	64.9±16.1	0.0304
	T3	11(25.0%)	70.6±15.0	T4 vs T1
	T4	12(27.3%)	126.5±29.7	0.0136
Stage				
	III	32 (72.7%)	84.9±13.5	0.2641
	IV	12 (27.3%)	55.7±17.0	
Bone metastasis				
	negative	36 (81.8%)	75.6 ±12.7	0.4559
	positive	8 (18.2%)	88.6±23.9	
No. of metastasis sites				
	one	5 (41.7%)	28.8±7.6	0.4649
	more than two	7 (58.3%)	77.0±26.8	
Lymph node metastasis				
	N0	2 (4.7%)	14.0±5.0	N3 vs N2
	N2	18 (41.9%)	49.7±10.9	0.0091
	N3	23(53.5%)	108.7±17.3	
Performance status				
	0	9 (25.7%)	59.9±21.7	NS
	1	22 (62.9%)	66.7±13.7	
	2	4(11.4%)	104.5±27.3	
LDH		27		0.6752
	466.9±291.2 U/l			$r^2=0.0074^*$
CEA		17		0.7287
	7.7±16.7 ng/ml			$r^2=0.088^*$

* Correlation with periostin levels for all patients monitored for this parameter

NS, not significant; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen

The mean values for serum periostin in breast cancer patients were: at stage II, 56.1 ± 14.3 ng/ml; at stage III, 28.0 ± 4.7 ng/ml; and at stage IV, 85.3 ± 20.5 ng/ml (Table 1). In normal healthy volunteers ($n=20$) a mean serum periostin level of 38.5 ± 5.8 ng/ml was observed. No significant difference in serum periostin levels was found between these groups.

Patient groups were further stratified according to established prognostic factors. Serum periostin levels were elevated in breast cancer patients with bone metastases (89.3 ± 21.8 ng/ml) compared to patients without evidence of bone metastasis (55.0 ± 16.6 ng/ml; $p=0.04$) (Table 1). However, there were no significant differences in the serum periostin levels according to estrogen or progesterone receptor status ($p=0.8359$ and 0.9758 , respectively), tumor grading ($p=0.1890$), menopausal status ($p=0.4309$), single vs. multiple metastatic sites ($p=0.2546$), the presence of lymph node metastases ($p=0.5411$), or the original tumor size (T) status (T1 - T4). A T1 lung tumor is 3.0 cm or less in its greatest dimension, is surrounded by lung or visceral pleura, and is without evidence of invasion proximal to a lobar bronchus at bronchoscopy. A T2 lung tumor is greater than 3.0 cm in its greatest dimension or is a lung tumor of any size that either invades the visceral pleura or has associated atelectasis or obstructive pneumonitis extending to the hilar region. At bronchoscopy, the proximal extent of demonstrable tumor must be within a lobar bronchus or at least 2.0 cm distal to the carina. Any associated atelectasis or obstructive pneumonitis must involve less than entire lung. A T3 lung tumor is (a) a tumor of any size with direct extension into the chest wall (including the superior sulcus tumors), diaphragm, or the mediastinal pleura or pericardium without involving the heart, great vessels trachea, esophagus or vertebral body, or (b) a tumor in the main bronchus within 2 cm of carina without involving the carina, or associated atelectasis or obstructive pneumonitis of the entire lung. A T4 lung tumor is a tumor of any size with invasion of the mediastinum or involving heart, great vessels, trachea, esophagus, vertebral body, or carina or presence of malignant pleural or pericardial effusion, or with satellite tumor nodules within the ipsilateral, primary tumor lobe of the lung.

There was also no significant difference in periostin levels in HER-2-positive ($n=4$) vs. HER-2-negative ($n=8$) patients ($p=0.3958$) although sample size of patients studied was limited.

The mean serum periostin levels in patients with small cell lung cancer were 84.9 ± 13.5 ng/ml for stage III and 55.7 ± 17.0 ng/ml for stage IV patients (Table 2). There was no significant

difference between stages of disease or between the patients and normal controls. Significant differences in serum periostin levels were seen, however, between patients with different T-status (tumor size status) and N-status (lymph node metastasis status). Serum periostin levels were elevated in T4 patients (126.5 ± 29.7 ng/ml) compared to T2 (64.9 ± 16.1 ng/ml, $p=0.03$) and T1 (36.3 ± 7.5 ng/ml, $p=0.01$). The difference in serum periostin levels in patients with N3 status (108.7 ± 17.3 ng/ml) was significantly different from those with N2 status (49.7 ± 10.9 ng/ml, $p=0.01$). Serum periostin levels were not different in lung cancer patients with bone metastases (88.6 ± 23.9 ng/ml) compared to patients who had no evidence of bone metastasis (75.6 ± 12.7 ng/ml). There were also no significant differences in serum periostin levels according to parameters such as gender ($p=0.3349$), performance status (ability to carry out physical activity) (PS 0-2), or one metastatic site vs. two or more metastatic sites ($p=0.4649$). Periostin levels did not correlate with the levels of either lactate dehydrogenase (LDH) or carcinoembryonic antigen (CEA).

Example 5. Expression of periostin mRNA in normal human tissues

Periostin mRNA was detected by RT-PCR in RNA from the human lung, kidney and placenta. However, it was not detectable in RNA from human heart, liver, brain and skeletal muscle. The DNA sequences of RT-PCR products from lung, kidney and placenta revealed forms of human periostin cDNA that differed from that (OSF-2) cloned from osteosarcoma [Takeshita et al. (1993) Biochem. J. 294:271-278]. The nucleotide sequence of cDNA (SEQ ID NO:1) encoding OSF-2 is shown in Fig. 1A and the amino acid sequence of OSF-2 (SEQ ID NO:2) is shown in Fig. 1B. Compared with OSF-2 cDNA, periostin cDNA cloned from placenta and lung had two deletions at residues 2009-2179 (171 base pairs, 57 amino acids) and residues 2360-2443 (84 base pairs, 28 amino acids), respectively. The nucleotide sequence of cDNA (SEQ ID NO:3) encoding this splice variant of periostin (designated periostin-L) is shown in Fig. 2A, and the amino acid sequence of periostin-L (SEQ ID NO:4) is shown in Fig. 2B. The nucleotide sequence of cDNA encoding the mature form of periostin-L (i.e., lacking nucleotides 1 to 63 of SEQ ID NO:3) is designated SEQ ID NO:5 and the amino acid sequence of mature periostin-L is designated SEQ ID NO:6. It is noted that nucleotide 2220 of SEQ ID NO:3 (and the corresponding nucleotide of SEQ ID NO:5) can be an A rather than a T residue. Periostin cDNA cloned from kidney had only one deletion at residues 2009-2179 (171 base pairs,

57 amino acids). The nucleotide sequence of cDNA (SEQ ID NO:7) encoding this splice variant of periostin (periostin-K) is shown in Fig. 3A, and the amino acid sequence of periostin-K (SEQ ID NO:8) is shown in Fig. 3B. The nucleotide sequence of cDNA encoding the mature form of periostin-K (i.e., lacking nucleotides 1 to 63 of SEQ ID NO:7) is designated SEQ ID NO:9, and the amino acid sequence of mature periostin-K is designated SEQ ID NO:10. It is noted that nucleotide 2304 of SEQ ID NO:7 (and the corresponding nucleotide of SEQ ID NO:9) can be an A rather than a T residue. All the above deletions are in-frame deletions. The periostin clones from placenta and lung lacked part of an α -helix site (residues 2403-2466) that could be involved in attachment to the cell extracellular matrix. *In situ* hybridization revealed periostin mRNA localized in the stroma of normal placenta tissue.

Example 6. Serum periostin levels in patients with preeclampsia

The clinical characteristics of the study sample of women with preeclampsia and normal pregnant women are shown in Table 3. There was no significant difference in pre-pregnancy body weight, hematocrit, or placenta weight at delivery between the groups. As required by the classification criteria used in this study, significant differences between the groups with preeclampsia and the normal pregnant group were noted for both systolic and diastolic blood pressures.

A significant difference in the age was noted between the groups. The mean age at delivery in the group with preeclampsia was 29.8 ± 1.2 years while that of normal pregnant group was 22.8 ± 0.7 years. There was, however, no significant correlation between maternal periostin levels and age at delivery in either group. There was a significant statistical difference in the mean birth weight between the infants of the women with preeclampsia (2240.1 ± 183.9 g) and those of normal pregnant women (3413.3 ± 78.7 g). However, there was no significant correlation between maternal periostin levels and infant body weight.

Serum periostin concentrations were elevated in preeclampsia patients (311.8 ± 56.3 ng/ml) compared to normal pregnant women at term (218.8 ± 37.3 ng/ml). The mean serum periostin concentration for normal healthy nonpregnant volunteers (n=20) was previously found to be 38.5 ± 6.1 ng/ml. Periostin concentrations in pregnant volunteers in the first trimester (n=58) were 77.5 ± 13.7 ng/ml. Thus, serum periostin concentrations in preeclampsia patients and in normal pregnant women at term were elevated compared to nonpregnant ($p=0.0001$) and first trimester

pregnant subjects ($p=0.01$). Concentrations in early pregnant and nonpregnant women were not significantly different. Other factors were also determined (Table 3). Serum TGF- β 1 levels were higher in preeclampsia patients ($8.0\pm 0.3\text{ng/ml}$) than in normotensive pregnant women ($7.2\pm 0.3\text{ng/ml}$, $p=0.0406$). However, TGF- β 1 concentrations did not correlate with periostin concentrations ($r=0.03$, $p=0.82$). The concentrations of serum VCAM-1 ($1.74\pm 0.12\text{mg/ml}$ vs. $1.28\pm 0.07\text{mg/ml}$, $p=0.0018$) and E-selectin ($50.4\pm 4.3\text{ng/ml}$ vs. $32.0\pm 3.6\text{ng/ml}$, $p=0.0007$) were significantly elevated in preeclampsia patients compared to normotensive pregnant women. Their levels also did not correlate with serum periostin levels. The level of interleukin-6 in serum of preeclampsia patients ($0.86\pm 0.17\text{ng/ml}$) was lower than in normal pregnant women ($1.33\pm 0.20\text{ng/ml}$), although the difference did not reach the level of significance selected. Interleukin-6 and periostin concentrations did not correlate.

TABLE 3. CLINICOPATHOLOGICAL DATA ON 30 PATIENTS WITH PREECLEMPSIA AND 30 NORMOTENSIVE PREGNANT WOMEN

Factors	total	60 women	(100%)
	preeclampsia 30(50%)	normal 30(50%)	p-value
Age at delivery(years)	29.8±1.2	22.8±0.7	0.0001
Body weight before pregnant(kg)	67.9±3.1	69.8±1.2	0.7449
Maternal predelivery hematocrit(%)	36.1±0.7	36.4±0.6	0.5894
Maternal predelivery Platelet	182.6±9.5	250.1±14.9	0.0003
Placenta weight (g)	318.4±19.0	438.3±59.3	0.06
Birth weight (g)	2240.1±183.9	3413.3±78.7	0.0001
Systolic blood pressure at delivery(mmHg)	157.1±2.0	121.3±1.8	0.0001
Diastolic blood pressure at delivery(mmHg)	93.8±1.4	72.2±1.7	0.0001
Maternal predelivery creatinine(mg/dL)	0.85±0.03	0.66±0.05	0.01
Gestational age at delivery (wk)	35.1±0.8	39.9±0.3	0.0001
Maternal predelivery uric acid	6.7±0.2	4.0±0.2	0.0005
Serum TGF-β1 levels	8.0±0.3	7.2±0.3	0.0406
correlation with periostin			0.82 r=0.03
Serum VCAM-1 levels	1.74±0.12	1.28±0.07	0.0018
correlation with periostin			0.5229 r=0.085
Serum E-selectin levels	50.5±4.3	32.0±3.6	0.0007
correlation with periostin			0.1852 r=0.173
Serum Interleukin-6 levels	0.86±0.17	1.33±0.20	0.0591
			0.5649 r=0.076
Serum Periostin levels (ng/ml)	311.2±56.3	218.8±37.3	0.0385

Example 7. Isolation of TCG1 cDNA from human colon carcinoma

TCG1 mRNA was initially identified as being overexpressed in human colon cancers (compared to normal colon tissue) using a palindromic PCR cDNA display technique. Briefly,

paired mRNA preparations from human colon carcinoma tissue and from the adjacent normal colon tissue from the same patient were reverse transcribed and the resulting cDNA amplified by palindromic PCR. Amplified PCR cDNA fragments (³⁵S-labeled) were resolved on a polyacrymide electrophoretic gel. The cDNA patterns for tumor and normal tissue were similar, though one expressed cDNA fragment was identified to be dominant in the tumor tissue but not in the adjacent normal tissue. This cDNA fragment was recovered from the polyacrymide gel and then reamplified with the same primer (PP12) used for the cDNA display. The reamplified cDNA fragment was then cloned in the PCR2.1 TA cloning vector (Invitrogen, Groningen, Germany). Nucleotide sequence analysis revealed that this fragment contained 636 bp with the same PP12 primer at both 5'-ends of the double stranded cDNA.

The full-length cDNA was obtained by screening a human colon carcinoma-derived cDNA library (Lambda ZAP II) with the 636 bp TCG1 fragment as a probe. A full-length clone was found to have an open reading frame of 2313 bp encoding a 771 amino acid sequence with a predicted molecular weight of 85 kDa. The nucleotide sequence of cDNA encoding TCG1 (SEQ ID NO:11) is shown in Fig. 4A and the amino acid sequence of TCG1 (SEQ ID NO:12) is shown in Fig. 4B. TCG1 cDNA lacks nucleotides 2009-2089 and 2349-2432 of OSF-2 cDNA (SEQ ID NO:1). In addition, while OSF-2 cDNA has 6 A residues at positions 2472-2477, TCG1 cDNA has 7 A residues in the corresponding subsequence. Thus, TCG1 protein: (1) lacks amino acids 670-726 of SEQ ID NO:2 and has an arginine residue in place of this subsequence (due to the deletion of nucleotides 2009-2089 of SEQ ID NO:1); (2) lacks amino acids 783-810 of SEQ ID NO:2 (due to the deletion of nucleotides 2349-2432 of SEQ ID NO:1); and (3) replaces amino acid residues 823-836 of SEQ ID NO:2 with the amino acid sequence SSRI (SEQ ID NO:18) (due to the extra A residue in the TCG1 cDNA sequence, which results in a frame shift and a premature stop codon). Furthermore, the first nucleotide of last codon of the TCG1 coding region (SEQ ID NO:11) can be a T rather than an A. In this case, the last amino acid of TCG1 is F rather than I. Amino acid sequence analysis revealed that TCG1 contains an N-terminal signal peptide (SP) or secretory leader sequence, followed by a cysteine-rich domain (CRD), four internal homologous repeats (each about 135 amino acids in length) and a hydrophilic C-terminal domain (Fig. 5). It is in the hydrophilic C-terminal domain that heterogeneity between the periostin variants occurs. One chemokine B family motif (C-C) was found in the cysteine-rich domain at amino acid residues 79-80. The protein contains one predicted site of N-linked

glycosylation (NDT) at amino acid residue 599-601. The signal peptide at the N-terminus and lack of a transmembrane domain suggest that it is a secreted protein. Western blot analysis of culture medium of cells expressing TCG1 confirmed that it is indeed a secreted protein. The nucleotide sequence of cDNA encoding mature TCG1 (i.e., lacking nucleotides 1 to 63 of SEQ ID NO:11) is designated SEQ ID NO:13 and mature TCG1 is designated SEQ ID NO:14.

A database search with the deduced amino acid sequence revealed that it is a splice variant of the human homologue of the mouse OSF-2 which was identified from MEC-3T3 osteoblast cells by subtractive screening [Takeshita et al. (1993) *Biochem J*, 294:271-278]. Northern blot analysis revealed that this protein is not osteoblast specific. To avoid confusion of OSF-2 with the Osteoblast Specific Transcription Factor OSF2/Cbfa1, the protein was designated TCG1 (TGF- α - and TGF- β -regulated and Cancer-associated Gene 1). Further analysis indicated that the TCG1 has significant structural and sequence homology with β igH3, a TGF- β inducible gene initially identified from human lung carcinoma A5409 cells [Skonier et al. (1992) *DNA Cell Biol*, 11:511-522]. TCG1 shares 45.2% identity or 82.9% similarity with β igH3 at the amino acid level (DNASTAR algorithm; Madison, WI). However, TCG1 contains an additional hydrophilic domain at the C-terminus. In addition, the β igH3 protein contains an RGD sequence at the C-terminus [Skonier et al. (1992) *DNA Cell Biol*, 11:511-522] that TCG1 does not contain. The amino acid sequence homology and structural similarity between TCG1 and β igH3 indicate their functional similarity. However, divergent amino acid sequences at the C-termini may reflect functional differences between the two proteins. Indeed, the expression patterns in various cell lines of TCG1 and β igH3 are very different. In addition, regulation of their expression by growth factors differs. Interestingly, both TCG1 and β igH3 share significant homology with Fasciclin I from Grasshopper and *Drosophila* [Bastiani et al. (1987) *Cell*, 48:745-755; Zinn et al. (1988) *Cell*, 53:577-587]. Fasciclin I is an extrinsic membrane glycoprotein involved in growth cone guidance during nervous system development in the insect embryo.

Example 8. Overexpression of TCG1 in human colon carcinomas and breast cancers

27 pairs of total RNA samples separately isolated from human primary colon tumor tissue (T) and their adjacent normal colon tissue (N) were examined by Northern Blot analysis with a 32 P-labeled TCG1 probe. In 24 of the 27 matched pairs, the TCG1 mRNA expression level was much greater in the tumor tissue than in the adjacent normal colon tissue. Further

analysis of the expression pattern indicated that the T/N ratio (tumor/normal ratio) of TCG1 mRNA in the 27 cases ranged from 3.8 to 42. The mean T/N ratio was 16.5. To test for a possible correlation between the T/N ratio of TCG1 mRNA and the disease stage of colon cancer, the T/N ratios were plotted against the stages of disease. The data indicated no correlation between higher T/N ratios of TCG1 mRNA expression with later stages of the disease. However, in all 5 cases with recurrent colon cancer, the T/N ratios were significantly higher than the average. The T/N ratio in these 5 cases ranged from 22.4 to 42 (mean = 29.6). This result suggested that high level of expression of TCG1 mRNA in tumor cells is associated with recurrence of the tumor. A higher frequency of tumor recurrence usually indicates stronger tumorigenicity of relevant cancer cells. Malignant colon carcinoma frequently metastasizes to the liver. To test the expression pattern of TCG1 mRNA in these metastatic colon tumors, six pairs of total RNA samples from metastatic colon carcinomas and their adjacent normal liver tissues were examined by Northern Blot analysis with a TCG1 cDNA probe. The level of TCG1 mRNA was much greater in the metastatic tumors than in the adjacent normal liver tissue in all 6 cases. Indeed, TCG1 mRNA was not detectable in normal liver tissue in 5 of the 6 cases studied.

Example 9. Increased levels of periostin in the sera of a panel of lung cancer patients

The levels of periostin in the sera of 116 lung cancer (small cell lung carcinoma, non-small cell lung carcinoma, squamous cell carcinoma, and large cell carcinoma) patients were measured using a modification of the chemiluminescence assay described above. As in the assay described above, the 5H8 monoclonal antibody was used as a "capture" antibody. In contrast, however, the 8H11 monoclonal antibody (rather than the E17 polyclonal antibody) was used as a "detection" antibody. In the breast cancer study performed using the E17 polyclonal antibody as a detection antibody, a mean serum periostin level in a group of 20 normal subjects of 38.5 ± 5.8 ng/ml was observed. On the other hand, using the 8H11 monoclonal antibody as a detection antibody in the study on lung cancer patients, sera from 76% of the patients gave chemiluminescence values not significantly different from values observed for assay wells to which assay buffer (instead of a serum sample) was added. Thus, the "normal" serum level of periostin, as measured in the assay using the 8H11 monoclonal antibody as a detection antibody,

was essentially 0. Importantly, this assay was sufficiently sensitive to detect a serum periostin level of only 2 ng/ml (see patient no. 16 in Table 4 below)

Of the 116 lung cancer patients studied, 28 (24%) had significantly increased serum periostin levels. The serum periostin levels detected in these 28 patients are shown in Table 4. Of the 116 patients, 6 (5%) had serum periostin levels greater than 1,000 ng/ml and 22 (19%) had serum periostin levels of between 1 ng/ml and 400 ng/ml. Notably, all the patients with serum periostin levels higher than 1,000 ng/ml died within a year of initial testing. In contrast, those showing serum periostin levels between 1ng/ml and 400 ng/ml, at least ten of whom were first tested more than a year before the time of writing, continue to be monitored at the time of writing.

TABLE 4. SERUM PERIOSTIN LEVELS IN 28 LUNG CANCER PATIENTS

<u>Patient No.</u>	<u>Serum periostin level (ng/ml)</u>
1	>1,000
2	>1,000
3	>1,000
4	>1,000
5	>1,000
6	>1,000
7	81
8	73
9	80
10	130
11	190
12	190
13	220
14	113
15	32
16	2
17	91
18	87
19	3
20	120
21	235
22	184
23	470
24	74
25	120
26	80
27	68
28	182

These data indicate that a body fluid (e.g., blood or urine) level of periostin can be a useful marker for lung cancer and that a high serum level (e.g., greater than 1,000 ng/ml) of periostin is indicative of a poor prognosis for lung cancer patients.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

WHAT IS CLAIMED

1. A purified antibody that binds specifically to human periostin.
2. The antibody of claim 1, wherein the antibody is a polyclonal antibody
3. The antibody of claim 1, wherein the antibody is a monoclonal antibody (mAb).
4. The antibody of claim 3, wherein the mAb is secreted by the 5H8 hybridoma (ATCC accession no. CRL-2646) or by the 8H11 hybridoma (ATCC accession no. _____).
5. A hybridoma that secretes a mAb that binds to human periostin.
6. The hybridoma of claim 5, wherein the hybridoma is the 5H8 hybridoma (ATCC accession no. CRL-2646) or the 8H11 hybridoma (ATCC accession no. _____).
7. A method of detecting human periostin in a sample, the method comprising
 - (a) contacting the sample with an antibody that binds to human periostin; and
 - (b) determining whether the antibody binds to a component of the sample,wherein binding of the antibody to a component of the sample indicates the presence of periostin in the sample.
8. The method of claim 7, further comprising, prior to contacting the sample with the first antibody that binds to human periostin, contacting the sample with a second antibody that binds to human periostin, wherein an epitope on human periostin to which the first antibody binds is not the same as an epitope to which the second antibody binds.
9. The method of claim 8, wherein the second antibody is bound to a solid substrate.
10. The method of claim 7, wherein the antibody is a polyclonal antibody.
11. The method of claim 7, wherein the antibody is a mAb.
12. The method of claim 11, wherein the mAb is a mAb that is secreted by the 5H8 hybridoma (ATCC accession no. CRL-2646) or by the 8H11 hybridoma (ATCC accession no. _____).

13. The method of claim 8, wherein the second antibody is a mAb.
14. The method of claim 13, wherein the mAb is a mAb that is secreted by the 5H8 hybridoma (ATCC accession no. CRL-2646) or by the 8H11 hybridoma (ATCC accession no. _____).
15. The method of claim 8, wherein the second antibody is a polyclonal antibody.
16. The method of claim 7, wherein the method comprises an immunoblot assay.
17. The method of claim 7, wherein the method comprises an ELISA assay.
18. The method of claim 7, wherein the detecting step comprises detecting chemiluminescence.
19. The method of claim 7, wherein the detecting step comprises detecting radioactivity or fluorescence.
20. The method of claim 7, wherein the detecting step comprises measuring absorbance of visible or ultraviolet light.
21. The method of claim 7, wherein the antibody is biotinylated.
22. The method of claim 7, wherein the detecting step comprises the use of avidin.
23. The method of claim 7, wherein the detecting step comprises the use of an antibody that binds to an immunoglobulin molecule.
24. A method of diagnosing a metastasis of breast cancer to bone, the method comprising:
 - (a) identifying a breast cancer patient suspected of having or being at risk of having a metastasis of breast cancer to bone; and
 - (b) measuring the level of periostin in a sample of a body fluid from the patient, wherein an elevated level of periostin in the sample, compared to a control level of periostin, is an indication that the patient has a metastasis of breast cancer to the bone.
25. The method of claim 24, wherein the body fluid is blood.

26. The method of claim 24, wherein the body fluid is urine.
27. A method of diagnosing preeclampsia in a patient, the method comprising:
 - (a) identifying a pregnant patient suspected of having or being at risk of having preeclampsia; and
 - (b) measuring the level of periostin in a sample of a body fluid from the patient, wherein an elevated level of periostin in the sample, compared to a control level of periostin, is an indication that the patient has preeclampsia.
28. The method of claim 27, wherein the body fluid is blood.
29. The method of claim 27, wherein the body fluid is urine.
30. An isolated DNA comprising a nucleic acid sequence encoding a polypeptide comprising SEQ ID NO:6 or SEQ ID NO:14.
31. The isolated DNA of claim 30, wherein the nucleic acid sequence is SEQ ID NO:5 or SEQ ID NO:13.
32. The isolated DNA of claim 30, wherein the DNA comprises a nucleic acid sequence encoding a polypeptide comprising SEQ ID NO:4 or SEQ ID NO:12.
33. The isolated DNA of claim 32, wherein nucleic acid sequence is SEQ ID NO:3 or SEQ ID NO:11.
34. A vector comprising the DNA of claim 30.
35. The vector of claim 34, wherein the nucleic acid sequence is operably linked to a transcriptional regulatory element (TRE).
36. A cell comprising the vector of claim 35.
37. An isolated polypeptide comprising SEQ ID NO:6 or SEQ ID NO:14.
38. The isolated polypeptide of claim 37, comprising SEQ ID NO:4 or SEQ ID NO:12.
39. An antigenic fragment of the polypeptide of claim 37, wherein the fragment:

(a) is shorter than the full-length polypeptide; and
(b) includes, consecutively, residues 725 and 726 of SEQ ID NO:4 or includes, consecutively, residues 768-771 of SEQ ID NO:12.

40. A method of making a polypeptide, the method comprising:

- (a) culturing the cell of claim 36; and
- (b) isolating the polypeptide from the culture.

Fig. 1A

atgattccctttttacccatgttttctctactattgtctgttattgttaaccctataaacgccacaatcattatgacaagatcttggctcat
agtcgtatcagggtcgaggaccaaggcccaaatgtctgtgcccttaacagattttgggcacaaaaagaaatacttcagcactt
gtaagaactgggtataaaaagtccatctgtggacagaaaacgactgtttatatgaatgttgccttggttatgagaatggaaggaa
tgaaaggctgccagcagttttgccattgaccatgtttatggcactctggcatogtgggagccaccacaacgcagcgtattct
gacgcctcaaaactgagggaggagatcgagggaaagggtaccttacttgcaccgagtaatgaggcttgggacaacttg
gattctgatatccgtagaggtttggagagcaacgtgaatgttgaaattcgaatgctttacatagtcacatgattaataagagaatgtt
gaccaaggacttaaaaaatggcatgatttcttcaatgtataacaatttggggctttcattaaccattatcctaattgggggtgtcac
tgttaattgtgctcgaatcatccatgggaaccagattgcaacaatgggtgttccatgtcattgaccgtgtgcttacacaaattggta
cctcaattcaagacttcattgaagcagaagatgaccttcatcttttagagcagctgccatcacatcgacatattggaggcccttg
gaagagacgggtcacitcacactctttgctcccacaaatgaggcttttgagaaactccacgaggtgtcctagaagggttcattggga
gacaaagtggctccgaagctcttatgaagtaccacatcttaatactctccagtgtctgagcttatttgggaggagcagctttg
agacgtgggaaggaaatacaattgagataggatgtgacgggtgacagtataacagtaaatggaatcaaaatgggtgaacaaaaag
gatattgtgacaaataatgggtgtgattcattgattgacaggtcctaattcctgattctgccaacaagttattgagctggctggaaa
acagcaaaccaccttcacggatctgtggcccaattaggcttggcatctgctctgaggccagatggagaatacacttgcctggca
cctgtgaataatgcattttctgatgatactctcagcatggttcagcgctccttaattaattctgcagaatcacatattgaagtaaaa
gttggccttaatgagctttacaacgggcaatactggaaaccatcgaggcaaacagctcagagcttctgatatcgtacagctgt
ctgcattgaaaattcatgcatggagaaaggagtaagcaaggagaaacgggtgcattcacatattccgcgagatcatcaagcc
agcagagaaatccctcatgaaaagttaaaacaagataagcgttttagcaccttctcagcctactgaagctgcagacttgaaa
gagctcctgacacaacctggagactggacattatttggccaaccaatgatgcttttaagggaatgactagtgaagaaaaagaaat
tctgatacgggacaaaaatgctcttcaaaacatcattctttatcacctgacaccaggagttttcattggaaaaggattgaacctggt
gttactaacattttaagaccacacaaggaagcaaaatcttttgaaagaagtaaatgatacacttctggtgaatgaattgaaatca
aaagaatctgacatcatgacaacaaatgggtgaattcatgtttagataaaactcctctatccagcagacacacctgttggaatgat
caactgtggaaatacttaataaattaatcaatacatccaaattaagtttctggtgtagcaccttcaaagaaatccccgtgactgt
ctatacaactaaaattataccaaagtgttggaacaaaaattaaagtattgaaggcagctctcagcctattatcaaaactgaagg
accacactaacaaaaagtcaaaattgaaggtaacctgaattcagactgattaagaagggtgaacaataactgaagtatccat
ggagagccaattattaaaaatacaccaaaatcattgatggagtgcctgtggaataactgaaaaagagacacgagaagaacg
aatcattacaggtcctgaaataaaaatacactaggatttctactggaggtggagaaacagaagaactctgaagaaattgttacaag
aagaggtcaccaagggtcaccaaatcattgaagggtggtgatggtcatttattgaagatgaagaaattaaaagactgcttcaggga
gacacaccgtgaggaagtgcaagccaacaaaaagttcaaggttctagaagacgattaagggaagggtcgttctcag

Fig. 1B

MIPFLPMFSLLLLLIVNPNANNHYDKILAHSRIRGRDQGPNVCALQQILGTKKKY
FSTCKNWKYSICGQKTTVLYECCPGYMRMEGMKGCPAVLPIDHVYGTLGIVG
ATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNA
LHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIIHGNQIAT
NGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITSDILEALGRDGHFTLFAPTN
EAFEKLPRGVLERFMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEI
GCDGDSITVNGIKMVNKKDIVTNNGVHILIDQVLIPDSAKQVIELAGKQQTTFD
LVAQLGLASALRPDGEYTLAPVNNAFSDDTLSMVQRLLKLILQNHILKVKVGL
NELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSKQGRNGAIHIFREIKPAE
KSLHEKCLKQDKRFSTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEI
LIRDKNALQNIILYHLTPGVFIGKGFEPGVNLTQGGSKIFLKEVNDTLLVNELK
SKESDIMTTNGVIHVVDKLLYPADTPVGNDQLEILNKLKIKYIYIKFVRGSTFKEIP
VTVYTTKIITKVVEPKIKVIEGSLQPIKTEGPTLTKVKIEGEPEFRLIKEGETITEVI
HGEPIKKYTKIIDGVPVEITEKETREERIITGPEIKYTRISTGGGETEETLKLLQEE
VTKVTKFIEGGDGHLEFDEEIKRLLQGDTVPVRKLQANKKVQGSRRRLREGRSQ

Fig. 2A

atgattccctttttacccatgttttcttactattgctgcttattgttaacctataaacgccacaatcattatgacaagatcttggctcat
agtcgtatcaggggtcgggaccaaggcccaaatgtctgtgcccttaacagattttgggcaccaaaaagaatacttcagcactt
gtaagaactggtataaaaagtcacatctgttgacagaaaacgactgtttatatgaatgttgccctggttatatgagaatggaaggaa
tgaaaggctgccagcagttttgccattgaccatgtttatggcactctgggcacgtgggagccaccacaacgcagcgctattct
gacgcctcaaaactgagggaggagatcgagggaaagggatccttactttgcaccgagtaatgaggcttgggacaacttg
gattctgatatccgtagagggttggagagcaacgtgaatgttgaattactgaatgctttacatagtcacatgattaataagagaatgtt
gaccaaggacttaaaaaatggcatgattatccttcaatgtataacaatttggggccttttcattaaccattatcctaattgggggtgtcac
tgttaattgtgctcgaatcatccatgggaaccagattgcaacaatgggtgtgtccatgtcattgaccgtgtgcttacacaaattggta
cctcaattcaagacttcattgaagcagaagatgaccttcatcttttagagcagctgccatcacatcgacatattggaggcccttg
gaagagacggctcacttcacactcttctctccaccaatgaggcttttgagaaactccacgaggtgtcctagaaagggtcatggga
gacaagtggctccgaagctcttatgaagtaccacatcttaatacttccagtgttctgagtctattatgggaggagcagctttg
agacgttggaaggaaatacaattgagataggatgtgacgggtgacagtataacagtaaatggaatcaaaatgggtgaacaaaaag
gatattgtgacaaataatgggtgatccatttgattgatcaggtcctaattcctgattctgccaaacaagtattgagctggctggaaa
acagcaaaccaccttcacggatcttgggcccaattaggcttggcatctgctctgaggccagatggagaatacactttgtctggca
cctgtgaataatgcattttctgatgatactctcagcatggttcagcgctccttaaatattctgcagaatcacatattgaaagtaaaa
gttggccttaatgagctttacaacgggcaatactggaaccatcggaggcaaacagctcagagtcttcgtatatcgtacagctgt
ctgcattgaaaattcatgcatggagaaaggagtaagcaaggagagaacgggtgcgattcacatattccgcgagatcatcaagcc
agcagagaaatccctccatgaaaagttaaaacaagataagcgtttagcaccttccctcagcctacttgaagctgcagacttgaaa
gagctcctgacacaacctggagactggacattatttggccaaccaatgatgcttttaagggaatgactagtgaagaaaaagaaat
tctgatacgggacaaaaatgtcttcaaaacatcttctacacctgacaccaggagtgtttcattggaaaaggatttgaaacctggt
gttactaacattttaaagaccacacaaggaagcaaaatcttctgaaagaagtaaatgatacacttctggtgaatgaattgaaatca
aaagaatctgacatcatgacaacaatgggtgaattcatgtttagataaaactcctctatccagcagacacacctgttggaatgat
caactgctggaaatacttaataaataacacaaaatcattgatggagtgcctgtggaaataactgaaaaagagacacgagaagaacga
atcattacaggctcctgaaataaaatacactaggatttctactggagggtggagaacagaagaactctgaagaatgttacaaga
agaggtcaccaaggggaagttgcaagccaacaaaaaagtcaaggttctagaagacgattaagggaaggtcgttctcag

Fig. 2B

MIPFLPMFSLLLLLIVNPNANNHYDKILAHSRIRGRDQGPNV CALQQILGTKKKY
FSTCKNWKYSICGQKTTVL YECCPGYMRMEGMKGCPAVLPIDH VYGT LGIVG
ATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNA
LHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIHGNQIAT
NGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITSDILEALGRDGHFTLFAPTN
EAFEKLPRGVLERFMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEI
GCDGDSITVNGIKMVNKKDIVTNNGVIHLIDQVLIPDSAKQVIELAGKQQTTFD
LVAQLGLASALRPDGEYTLLAPVNNAFSDDTL SMVQRLLKLILQNHILKVKVGL
NELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSQGRNGAIHIFREIIPAE
KSLHEKCLKQDKRFSTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEI
LIRDKNALQNIILYHLTPGVFIGKGFEPGVNLTQGSKIFLKEVNDTLLVNELK
SKESDIMTTNGVIHVVDKLLYPADTPVGNDQLEILNKLIK YIQIKFVRGSTFKEIP
VTVYKPIKKYTKIIDGVPVEITEKETREERIITGPEIKYTRISTGGGETEETLKKLLQ
EGKLQANKKVQGSRRRLREGRSQ

Fig. 3A

atgattccctttttacccatgtttcttactattgtctgttattgttaaccctataaacgccaacaatcattatgacaagatcttggtcat
agtcgtatcaggggtcgggaccaaggcccaaatgtctgtgcccttcaacagattttgggcacaaaaagaaatacttcagcactt
gtaagaactggtataaaaagtcctctgtggacagaaaacgactgtttatatgaatgttgccctggttatatgagaatggaaggaa
tgaagggtgcccagcagtttgccttgaccatgtttatggcactctgggcacgtggggagccaccacaacgcagcgtcttct
gacgcctcaaaaactgagggaggagatcagggaaaaggatccttacttgcaccgagtaatgaggcttgggacaacttg
gattctgatatccgtagaggttggagagcaacgtgaatgtgaattactgaatgctttacatagtcacatgattaataagagaatgtt
gaccaaggacttaaaaaatggcatgattattcctcaatgtataacaatttggggctttcattaaccattatcctaattggggtgtcac
tgtaattgtgctcgaatcatcctatgggaaccagattgcaacaatgggtgtgtccatgtcattgaccgtgtgcttacacaaattggta
cctcaattcaagacttcattgaagcagaagatgaccttcatcttttagagcagctgccatcacatcggacatatitggaggcccttg
gaagagacgggtcacttcacactcttgcctccaccaatgaggcttttgagaaactccacgaggtgtcctgaaagggttcatggga
gacaaagggtctccgaagctcttatgaagtaccacatcttaatactctccagtgttctgagctattatgggaggagcagctttg
agacgtggaaggaaatacaattgagataggatgtgacgggtgacagtataacagtaaatggaatcaaatggtgaacaaaaag
gatattgtgacaaataatggtgtgatccatttgattgatcaggtcctaattcctgattctgccaacaagtattgagctgggtgaaa
acagcaaaccaccttcacggatcttgtggccaattaggcttggcatctgctgaggccagatggagaatacaccttgcctggca
cctgtgaataatgcattttctgatgatactctcagcatggttcagcgctccttaattaattctgcagaatcacatattgaaagtaaaa
gttggccttaatgagctttacaacgggcaaatactggaaccatcggaggcaaacagctcagagtcttcgtatatcgtacagctgt
ctgcattgaaaattcatgcatggagaaaggagtaagcaaggggagaaacgggtgcgattcacatatitccgcgagatcatcaagcc
agcagagaaatccctccatgaaaagttaaacaagataagcgcttttagcaccttctcagcctacttgaagctgcagacttgaaa
gagctcctgacacaacctggagactggacattatttgcaccaaatgatgcttttaagggaatgactagtgaagaaaaagaaat
tctgatacgggacaaaaatgctcttcaaaacatcattctttatcacctgacaccaggagtttcttggaaaaggattgaacctggt
gttactaacattttaagaccacacaaggaagcaaaatcttctgaaagaagtaaatgatacacttctggtgaatgaattgaaatca
aaagaatctgacatcatgacaacaatgggtgaattcatgtttagataaaactcctctatccagcagacacacctgttggaatgat
caactgctggaaatacttaataaataatcaaatcatcctaattagttgttcgtgtagcaccttcaagaaatccccgtgactgt
ctataagccaattattaaaaatacaccaaaatcattgatggagtgccctgtggaaataactgaaaaagagacacgagaagaacga
atcattacaggtcctgaaataaaatacactaggatttctactggaggtggagaacagaagaactctgaagaaattgtacaaga
agaggtcaccaagggtcaccaaatcattgaagggtggtgatggtcatttattgaagatgaagaaattaaaagactgctcagggag
acacaccgtgagggaagtgcaagccaacaaaaaaggtcaagggtctagaagacgattaagggaaggtcgttctcag

Fig. 3B

MIPFLPMFSLLLLLIVNPNANNHYDKILAHSRIRGRDQGPNVCALQQILGTKKKY
FSTCKNWKYSICGQKTTVLYECCPGYMRMEGMKGCPAVLPIDHVYGTLGIVG
ATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNA
LHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIHGNQIAT
NGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITSDILEALGRDGHFTLFAPTN
EAFEKLPRGVLERFMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEI
GCDGDSITVNGIKMVNKKDIVTNNGVIHLIDQVLIPDSAKQVIELAGKQQTTFD
LVAQLGLASALRPDGEYTLLAPVNNAFSDDTLMSVQRLLKLILQNHILKVKVGL
NELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSKQGRNGAIHIFREIKPAE
KSLHEKCLKQDKRFSTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEI
LIRDKNALQNIILYHLTPGVFIGKGFEPGVNLTQGGSKIFLKEVNDTLLVNELK
SKESDIMTTNGVIHVVDKLLYPADTPVGNDQLEILNKLIK YIQIKFVRGSTFKEIP
VTVYKPIKKYTKIIDGVPVEITEKETREERIITGPEIKYTRISTGGGETEETLKKLLQ
EEVTKVTKFIEGGDGHLEFDEEIKRLLQGDTPVRKLQANKKVQGSRRRLREGRS
Q

Fig. 4A

7/9

atgattccctttttacccatgttttcttactattgtctgcttattgttaaccctataaacgccaacaatcattatgacaagatcttggctcat
agtcgtatcaggggtcgggaccaaggcccaaatgtctgtgcccttaacagattttgggcacccaaaaagaatacttcagcactt
gtaagaactgggtataaaaaagtcctctgttgacagaaaaacgactgtgttatatgaatgttgccttggttatatgagaatggaagga
atgaaaggctgccagcagttttgccattgaccatgtttatggcactctgggcacgtgggagccaccacaacgcagcgctatt
ctgacgcctcaaaactgagggaggagatcaggggaaaggatccttacttgcaccgagtaatgaggcttgggacaact
tggattctgatatccgtagagggttggagagcaacgtgaatgtgaattactgaatgctttacatagtcacatgattaataagagaat
gttgaccaaggacttaaaaaatggcatgattattccttcaatgtataacaatttggggcttttcattaaccattatcctaattgggggtgt
cactgttaattgtgtcgaatcatccatgggaaccagattgcaacaaatgggtgttgcctatgcatgaccgtgtgcttacacaatt
ggtaacctcaattcaagacttcattgaagcagaagatgaccittatcttttagagcagctgccatcacatcggacatattggaggcc
cttggagagacgggtcacttcacactcttctgccccaatgaggcttttgagaaactccacgaggtgtcctagaaaggatcat
gggagacaaagtggcttccgaagctcttatgaagtaccacatcttaataactctccagtgttctgagtctattatgggaggagcagt
ctttgagacgctggaggaataacaattgagataggatgtgacgggtgacagtataacagtaaatggaatcaaaatgggtgaacaa
aaaggatattgtgacaaataatgggtgtgatccatttgattgatcaggtcctaattcctgattctgccaacaagttattgagctggctg
gaaaacagcaaacacccttcacggatcttgggccaattaggcttggcatctgctctgaggccagatggagaatacactttgct
ggcacctgtgaataatgcattttctgatgatactctcagcatggatcagcgctccttaataaattctgcagaatcacatattgaaag
taaaagttggccttaatgagctttacaacgggcaataactggaaaccatcggaggcaaacagctcagagtcttctgtatctgtaca
gctgtctgcattgaaaattcatgcatggagaaaaggagtaagcaaggaggagaaacgggtgcgattcacatattccgcgagatcatc
aagccagcagagaaaatccctcatgaaaagttaaaacaagataagcgctttacgaccttctcagcctacttgaagctgcagact
tgaaaagagctcctgacacaacctggagactggacattttgtgccaaacatgatgcttttaagggaatgactagtgaagaaaaa
gaaattctgatacgggacaaaaatgctcttcaaacatcattctttatcacctgacaccaggagttttcattggaaaaggattgaac
ctgggtgttactaacattttaagaccacacaaggaagcaaaatcttctgaaagaagtaaatgatacacttctggtgaatgaattgaa
atcaaaagaatctgacatcatgacaacaaatgggtgaattcatgtttagataaaactcctctatccagcagacacacctgttgaaa
tgatcaactgctggaaatacttaataaaatfaatcaaatatccaaataagtttctgttgtagcaccttcaagaaatccccgtga
ctgtctatagaccacactaacaagaatgcaaaattgaagggtgaacctgaattcagactgattaaagaagggtgaacaataactga
agtgtatccatggagagccaattattaaaaatacaccaaaatcattgatggagtgccctgtggaataactgaaaagagacacga
gaagaacgaatcattacaggctctgaataaaatacactaggatttctactggaggtggagaaacagaagaactctgaagaat
tggtacaagaagacacaccctgtgaggaagttgcaagccaacaaaaaaagtcaaggatc

Fig. 4B

MIPFLPMFSLLLLLLIVNPINANNHYDKILAHSRIRGRDQGPNVCALQQILGTKKKY
FSTCKNWKKSICGQKTTVL YECCPGYMRMEGMKGCPAVLPIDHVVYGTLGIVG
ATTTQRYSDASKLREEIEGKGSFTYFAPSNEAWDNLDSDIRRGLESNVNVELLNA
LHSHMINKRMLTKDLKNGMIIPSMYNNLGLFINHYPNGVVTVNCARIIHGNQIAT
NGVVHVIDRVLTQIGTSIQDFIEAEDDLSSFRAAAITS DILEALGRDGHFTLFAPTN
EAFEKLPRGVLERIMGDKVASEALMKYHILNTLQCSESIMGGAVFETLEGNTIEIG
CDGDSITVNGIKMVNKKDIVTNNGVIHLIDQVLIPDSAKQVIELAGKQQTTFIDL
VAQLGLASALRPDGEYTL LAPVNNAFSDDTLSMDQRLLKLILQNHILKVKVGLN
ELYNGQILETIGGKQLRVFVYRTAVCIENSCMEKGSKQGRNGAIHIFREIKPAEK
SLHEKLKQDKRFTTFLSLLEAADLKELLTQPGDWTLFVPTNDAFKGMTSEEKEIL
IRDKNALQNIILYHLTPGVFIGKGFEPGVNLTQGGSKIFLKEVNDTLLVNELKS
KESDITMTNGVIHVVDKLLYPADTPVGNDQLEILNKLIK YIQIKFVRGSTFKEIPV
TVYRPTLT KVIEGEPEFRLIKEGETITEVIHGEPHKKYTKIIDGVPEITEKETREE
RIITGPEIKYTRISTGGGETEETLKKLLQEDTPVRKLQANKKSSRI




Fig. 5

专利名称(译)	基于骨膜素的诊断分析		
公开(公告)号	EP1442295A2	公开(公告)日	2004-08-04
申请号	EP2002757081	申请日	2002-08-13
[标]申请(专利权)人(译)	达那-法伯癌症研究所		
申请(专利权)人(译)	Dana-Farber癌症研究所INC.		
当前申请(专利权)人(译)	Dana-Farber癌症研究所INC.		
[标]发明人	CHEN LAN BO DAI MEIRU SASAKI HIDEFUMI AUCLAIR DANIEL		
发明人	CHEN, LAN BO DAI, MEIRU SASAKI, HIDEFUMI AUCLAIR, DANIEL		
IPC分类号	C07K14/47 C07K14/475 C07K14/52 C07K16/22 C07K16/24 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N15/09 C12P21/02 C12P21/08 G01N21/76 G01N21/78 G01N33/53 G01N33/543 G01N33/574 G01N33/577 G01N33/68		
CPC分类号	G01N33/689 C07K14/475 C07K16/22 G01N33/57415 G01N2800/368		
优先权	60/312123 2001-08-13 US		
其他公开文献	EP1442295A4 EP1442295B1		
外部链接	Espacenet		

摘要(译)

本发明包括新的人骨膜素多肽和编码它们的DNA。本发明还包括人骨膜素特异性抗体，乳腺癌向骨转移的诊断测定和先兆子痫。